We will have limited operations from 15:00 Wednesday 24 December 2025 (AEDT) until Friday 2 January 2026. Find out how to contact us during the holiday period.
ILUMYA (Sun Pharma ANZ Pty Ltd)
Product name
ILUMYA
Sponsor
Date registered
Evaluation commenced
Decision date
Approval time
227 working days (255)
Active ingredients
tildrakizumab
Registration type
NCE/NBE
Indication
ILUMYA (solution for injection) is indicated for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy.